Q-omics provides the consensus-scored SLITRK3 profile across patient tissues and cancer cell-line models. SLITRK3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLITRK3 is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, SLITRK3 RNA expression shows 11,316 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRP, and GBM as cancer lineages where SLITRK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLITRK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLITRK3 survival associations across molecular data types. SLITRK3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (13) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLITRK3 RNA expression–survival associations across cancer types. High SLITRK3 expression shows unfavorable associations in MESO, KICH, BLCA, KIRP, OV and CHOL. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SLITRK3 RNA expression.
This table summarizes SLITRK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SLITRK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLITRK3 shows lower tumor expression in KIRP, COAD, KIRC, THCA, KICH and UCEC. The KIRP box plot shows higher SLITRK3 RNA expression in normal versus tumor tissue (log2 FC = −0.155, t-test p < 0.001).
This table shows molecular features associated with SLITRK3 in patient tissues and cancer cell lines. In patient samples, SLITRK3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLITRK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
